Condition: Breast Cancer · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
This description comes directly from the study's public registry record.
Thomas Decker, Prof. · +49 751 366197 · Thomas.Decker@onkonet.eu
Regina Eickhoff, Dr. · +49 69 / 5899 787 · eickhoff.regina@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Charité Berlin | Berlin, Germany | Recruiting |
| Hämatologische Onkologische Praxis im Medicum | Bremen, Germany | Recruiting |
| St. Johannes Hospital Dortmund | Dortmund, Germany | Active Not Recruiting |
| Praxis und Tagesklinik | Friedrichshafen, Germany | Active Not Recruiting |
| Hausärztliche und Onkologische Gemeinschaftspraxis | Gerlingen, Germany | Recruiting |
| Onkologische GP Gütersloh | Gütersloh, Germany | Active Not Recruiting |
| Hämatologisch-Onkologische Praxis Altona | Hamburg, Germany | Recruiting |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Mainz, Germany | Recruiting |
| MVZ für Hämatologie und Onkologie der MVZ Mülheim GmbH | Mülheim, Germany | Recruiting |
| MVZ für Hämatologie und Onkologie | Ravensburg, Germany | Recruiting |
| Krankenhaus Barmherzige Brüder Regensburg | Regensburg, Germany | Recruiting |
| Onkologisch-Gastroenterologische Schwerpunktpraxis Innere Medizin GbR | Singen, Germany | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06207734